THERAPEUTIC POTENTIAL OF NAS150 IN ANIMAL HEALTH IS SIGNIFICANT  

New Amsterdam Sciences’ anti-inflammatory platform technology, consisting of compounds NAS150, NAS114, and NAS415, all Superoxide Dismutase (SOD) mimetics, has shown significant potential in the treatment of diseases where oxidative stress is involved. In particular, NAS150 has demonstrated the ability to scavenge a broad range of reactive oxygen species (ROS) and has been shown to reverse multiple biomarkers of inflammation, oxidative stress, and immune response associated with DNA oxidative damage, fibrosis, and central nervous system dysfunction in animal models..

The therapeutic potential of NAS150 in animal health is significant. Excess generation of reactive oxygen, nitrogen, and lipid species are believed to have an important role in the pathogenesis of many diseases, including those in animals. Therefore, NAS150 could potentially have a broad range of therapeutic uses in animals suffering from diseases where oxidative stress is involved. Presently, oxidative stress is an active field of research in veterinary medicine and has been implicated in numerous disease processes including sepsis, mastitis, enteritis, pneumonia, respiratory and joint diseases such as osteoarthritis and hip dysplasia. As our pets age, the tissues lining the joints may deteriorate and degenerate. Degenerative joint disease (DJD) refers to arthritis or osteoarthritis, which is the result of the gradual deterioration of the articular cartilage within one or more the joints. The global canine arthritis treatment market is at approximately $2.39 billion USD in 2022. Worldwide demand for canine arthritis treatments is predicted to rise at a CAGR of 4.2% to a valuation of $3.05 billion by 2028. One in five dogs is diagnosed with OA in their lifetime. The prevalence of OA in dogs over one year of age in North America is reported at 20% based on data collected from over 200 veterinarians.

New Amsterdam Sciences is focused on developing the compound as a potential therapeutic for animals such as dogs, cats, equine, etc. to treat pneumonia, FIV, infectious diseases and arthritis and Radiation-Induced Lung Injury (RILI) related to cancer therapies post targeted chemo or radiation procedures. FIV is one of the most common infectious diseases among cats. In North America, around 3-5% of healthy cats are FIV-positive. Similar to HIV in humans, the virus can weaken a cat’s immune system, making them vulnerable to other infections. NAS150 has Fast-Track Designation from the FDA for Lung Acute Radiation Syndrome. These indications in animals have been shown to be effectively treated with the use of NAS150.

For infectious disease NAS-150 could play a significant role in directly treating or as an adjunct to current gold standards used today for many emerging new infectious diseases, such as COVID-19, and ever-present disease threats such as Foot and Mouth Disease that affects cattle, pigs and sheep, and African Swine Fever which can devastate herds, impact the food supply, and harm the incomes of farmers who depend on animals for livelihoods.

Moreover, NAS114 has shown promise as a neuroprotective agent in animals suffering from CNS diseases like Parkinson’s Disease and Epilepsy. NAS114 mitigates depletion of the neurotransmitter dopamine and prevents loss of nigrostriatal dopaminergic neurons, the most important pathological features of Parkinson’s Disease patients. Additionally, NAS114 can penetrate the blood-brain barrier, making it an effective treatment for CNS diseases in animals when applicable.

Finally, NAS415 has been shown to have anti-inflammatory and anti-microbial properties while maintaining pathogen killing with less off-target

damage in animals. Studies have shown that NAS415 protects the lungs against infection in a mouse model of cystic fibrosis. Therefore, NAS415 could potentially have therapeutic applications in the treatment of various diseases in animals where inflammation and bacterial infections are involved.

Overall, NAS150, NAS114, and NAS415 show significant potential in improving animal health by reducing inflammation, oxidative stress, and immune response associated with various diseases. Some of the supportive funding for studies conducted on these compounds came from highly-respected organizations such as the National Institutes of Health, Biomedical Advanced Research and Development Agency, The Michael J. Fox Foundation, Cystic Fibrosis Foundation, and Citizens United for Research in Epilepsy Foundation, further underscores their potential as effective treatments for a wide range of diseases in animals.